Bollé Safety, the PPE Eyewear Specialists Introduce Go Green: Concrete Actions to Protect the Environment
25.5.2021 11:45:00 EEST | Business Wire | Press release
Bollé Safety wants to do its part to protect the planet. In 2021, the global brand for eye protection is kicking into high gear with their Go Green plan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210525005026/en/
Sustainability: a long-term process
Bollé Safety’s products have been packaged in recyclable BPA-free plastic bags since 2005. But as a company selling millions of units annually, they wish to do more on every aspect of their production and distribution processes.
With the Go Green program, all of their eco-friendly improvements add up to reach one goal: become a certified B Corporation by 2023, and meet the most rigorous standards of environmental performance, for their stakeholders benefits.
Focusing on green research and development
Their R&D and production departments are committed to developing more environmentally-friendly materials, products and processes, while always preserving the quality and protection they offer.
Introducing the Ecopack: 100% recyclable packaging made from recycled cardboard and tissue paper. The user-instruction is printed directly on the overwrap with vegetal-based ink to avoid all plastic. By optimizing their product design, they also reduce the amount of raw material required during production, as well as the packaging weight. It produces 30% less waste than before, improving their carbon footprint during transportation.
More sustainable technologies and raw materials
Focus on eco-friendly products: SOLIS and KLASSEE. With its nylon frame made from 100% recycled fishing nets, SOLIS is EN166-compliant and embodies the company’s R&D effort towards sustainability. KLASSEE’s (prescription) bio-based frame is made from castor oil.
Extra efforts: By using the latest technologies, they also reduce energy consumption and waste production during manufacturing (injection, molding). Some of the coatings are water-based to reduce the use of chemicals when possible.
Sustainability has never been more necessary than today. It is time for action. This is the reason why Bollé Safety decided, as a company, to become more conscious.
To find out more about our actions, visit https://bit.ly/3vuHanQ
About Bollé Safety
Bollé Safety, the global brand for eye protection since 1888.
With a wide range of innovative, comfortable and protective safety and prescription eyewear, we are trusted with the protection of over 20 million workers’ vision in 100 countries. It is our duty to make a difference, for you and for the future of our Planet.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005026/en/
Contact information
Press
Aline CAMPO/Robin SAUNIER-PLUMAZ
+33-(0)7-64-55-36-09/+33-(0)7-64-55-36-09
E-mail: press@bolle-safety.com
bolle-safety.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 16:00:00 EEST | Press release
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's core mission has always been to increase access to life-saving treatments. It’s about getting the right information to the right care tea
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 16:00:00 EEST | Press release
Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become operational infrastructure without corresponding security maturity. The report also reveals that AI environments are rapidly becoming more interconnected and business critical. Among organizations adopting AI, 64% now run vector databases, 55
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 16:00:00 EEST | Press release
As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructure to monitor airspace activity. The new 86,350-square-foot facility is a major step in readying supply for multiple, large, global markets. The
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 15:51:00 EEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus ® (ocrelizumab) for Multiple Sclerosis9.7.2026 15:45:00 EEST | Press release
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709701277/en/ “This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale,” said Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG. “Teva brings reach, discipline and real commercial strength to our strategic collaboration. Combining its global footprint with our technical and develo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom